The quest to develop drugs for previously “undruggable” targets is gaining momentum, fueled by advances in peptide innovation and a new cell-free platform that dramatically accelerates the screening process. For decades, researchers have struggled to find effective treatments for diseases driven by complex biology, with an estimated 85% of human protein targets considered beyond the reach of traditional drug development methods. But a growing focus on peptides – short chains of amino acids – is offering a promising path forward, and a new technology promises to speed up the discovery of these potential therapies.
Peptides, often described as nature’s own signaling molecules, possess a unique ability to interact with proteins with high precision. This inherent biological compatibility, combined with their chemical flexibility, makes them versatile candidates for treating a wide range of diseases. AstraZeneca is at the forefront of this research, recognizing the potential of peptides to modulate complex biological targets that have historically proven difficult to address. The company is actively working to accelerate peptide discovery and development through automation, high-throughput screening, and data-driven molecule design, aiming to create new medicines across multiple disease areas.
‘Drugging the Undruggable’ with Peptide Therapeutics
The challenge with many diseases lies in targeting the underlying proteins that drive them. Traditional small-molecule drugs often struggle to bind effectively to these proteins, while larger biologic therapies can face challenges with delivery, and manufacturing. Peptides offer a middle ground, combining the specificity of biologics with the tunability of small molecules. As AstraZeneca explains, this allows for the creation of therapies that can effectively engage these complex targets.
Beyond functioning as drugs themselves, peptides can also be engineered to act as delivery vehicles, directing other therapeutic modalities – such as targeted radiation or oligonucleotides – to specific cells and tissues within the body. This targeted approach minimizes off-target effects and maximizes therapeutic impact. This versatility is a key driver of the increasing interest in peptide-based therapies.
A Cell-Free Platform for Faster Screening
A significant bottleneck in peptide drug discovery has been the time-consuming process of screening potential candidates. Traditional methods often rely on cell-based assays, which can be slow and may not accurately reflect the complex environment within the body. Yet, a new cell-free platform is poised to overcome these limitations. According to Phys.org, this platform allows for faster screening of peptides, even under harsh conditions that would typically compromise cell viability.
This technology enables researchers to explore a wider range of peptide sequences and modifications, accelerating the identification of promising drug candidates. The ability to screen in harsh conditions is particularly valuable for identifying peptides that can target challenging disease environments, such as those found in tumors or inflamed tissues. The platform’s speed and robustness represent a significant leap forward in peptide drug discovery.
Syneron Bio and AstraZeneca Collaboration
The potential of macrocyclic peptides – a specific type of peptide with a ring-like structure – is also gaining recognition. Syneron Bio, a biotechnology company specializing in oral macrocyclic peptide drugs, has partnered with AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases. This collaboration highlights the growing interest in this class of compounds and their potential to address unmet medical needs.
Macrocyclic peptides often exhibit enhanced stability and bioavailability compared to linear peptides, making them attractive candidates for oral drug delivery. The partnership between Syneron Bio and AstraZeneca aims to leverage the strengths of both companies to accelerate the development of these innovative therapies.
The Future of Peptide Therapeutics
The integration of quantum computing is also emerging as a powerful tool in peptide therapeutics. Experts suggest that quantum computing can help to predict peptide structures and interactions with greater accuracy, further accelerating the drug discovery process. The Hindu reports that this integration represents a new era in the field, offering unprecedented capabilities for drug design and optimization.
The convergence of these advancements – innovative peptide design, cell-free screening platforms, and quantum computing – is transforming the landscape of drug discovery. As research continues, we can expect to observe a growing number of peptide-based therapies reaching the clinic, offering new hope for patients with previously untreatable diseases. The next key milestone will be the reporting of initial clinical trial data from AstraZeneca’s peptide programs, anticipated in late 2026 or early 2027.
Have thoughts on this story? Share your comments below.
